IQVIA Holdings Inc. $IQV Shares Sold by Aberdeen Group plc

Aberdeen Group plc cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 137,993 shares of the medical research company’s stock after selling 5,810 shares during the period. Aberdeen Group plc owned 0.08% of IQVIA worth $24,938,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Physician Wealth Advisors Inc. boosted its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. raised its holdings in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in IQVIA in the 3rd quarter worth approximately $36,000. Asset Dedication LLC increased its position in IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the period. Finally, Rothschild Investment LLC raised its stake in IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Morgan Stanley set a $240.00 target price on shares of IQVIA in a research note on Wednesday, February 11th. Jefferies Financial Group reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $238.20.

IQVIA Stock Down 1.5%

IQV stock opened at $164.44 on Wednesday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70. The firm has a market cap of $28.00 billion, a PE ratio of 20.92, a P/E/G ratio of 1.61 and a beta of 1.37. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The firm has a 50 day simple moving average of $220.91 and a 200 day simple moving average of $208.93.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.